Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | LAP3 | P28838 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288204 | 0.89 | SLC7A5 (0.52) | SLC7A5DPP4FAPDPP8DPP9 | |
| SCHEMBL10530419 | 0.89 | SLC7A5 (0.52) | SLC7A5DPP4FAPDPP8DPP9 | |
| SCHEMBL29388526 | 0.88 | SLC7A5 (0.48) | SLC7A5DPP4FAPDPP8DPP9 | |
| SCHEMBL8417265 | 0.86 | SLC7A5 (0.41) | SLC7A5DPP4FAPDPP8DPP9 | |
| SCHEMBL29269089 | 0.82 | SLC7A5 (0.46) | SLC7A5DPP4FAPDPP8DPP9 | |
| SCHEMBL28911829 | 0.82 | SLC7A5 (0.46) | SLC7A5DPP4FAPDPP8DPP9 | |
| SCHEMBL756027 | 0.82 | SLC7A5 (0.46) | SLC7A5DPP4FAPDPP8DPP9 | |
| SCHEMBL10710883 | 0.82 | SLC7A5 (0.46) | SLC7A5DPP4FAPDPP8DPP9 | |
| SCHEMBL1615114 | 0.82 | SLC7A5 (0.46) | SLC7A5DPP4FAPDPP8DPP9 | |
| SCHEMBL229820 | 0.82 | SLC7A5 (0.46) | SLC7A5DPP4FAPDPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232860-A1 | Medicine comprising dicyanopyridine derivative | ASTELLAS PHARMA INC. (JP) | 2003-12-18 | — | — | US | disclosed |
| EP-1302463-A1 | MEDICINE COMPRISING DICYANOPYRIDINE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232860-A1 | Medicine comprising dicyanopyridine derivative | KCNN3, KCNN2, KCNN1 | SLC7A5 1295/4885DPP4 584/4885FAP 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.